Related Experiment Videos
Relationship between plasma desipramine levels and clinical outcome for RDC major depressive inpatients
Abstract:
Depressed patients (N = 31), who met Research Diagnostic Criteria for major affective disorder-depressed, were severely ill and maintained drug-free for a 1-week period on inpatient status. They received a fixed dose (150 mg/day) of desipramine for a 4-week period with drug plasma level determination and clinical ratings performed at fixed time intervals throughout the study. Despite these rigid criteria for entrance and clinical outcome measures, no obvious relationship between plasma desipramine level and clinical outcome was found. The clinical implications of this finding are discussed.
Insights
This study found no clear link between desipramine drug levels and treatment outcomes in severely depressed patients. Further research is needed to understand antidepressant effectiveness.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Neuroscience
Background:
- Major depressive disorder is a significant global health concern.
- Antidepressant efficacy, particularly with tricyclic antidepressants like desipramine, can vary widely among individuals.
- Understanding factors influencing treatment response is crucial for optimizing patient care.
Purpose of the Study:
- To investigate the relationship between plasma desipramine levels and clinical outcomes in severely depressed patients.
- To assess the impact of a fixed desipramine dosage on treatment response.
- To explore the clinical implications of observed drug-level-outcome correlations.
Main Methods:
- Recruitment of 31 severely ill depressed patients meeting Research Diagnostic Criteria.
- A 1-week drug-free period followed by 4 weeks of fixed-dose (150 mg/day) desipramine treatment.
- Regular monitoring of drug plasma levels and clinical ratings at fixed intervals.
Main Results:
- No significant correlation was identified between plasma desipramine concentrations and clinical improvement.
- Patient outcomes varied despite adherence to rigid study criteria and fixed dosing.
- The study highlights potential complexities beyond plasma levels in desipramine treatment response.
Conclusions:
- Plasma desipramine levels may not be a reliable predictor of treatment outcome in all severely depressed patients.
- Individual patient factors likely play a significant role in antidepressant response.
- Further investigation into pharmacogenetics and other biomarkers is warranted to personalize depression treatment.